Best Poster (# B17- 0067): The German study group for gynaecologic oncology (AGO = arbeitsgemeinschaft gynäkologische onkologie) represented by G Emons [9], University Hospital Goettingen, presented its results to the Phase II-study with a targeted cytotoxic LHRH-analogue (AEZS-108) in patients with LHRH – receptor positive endometrial cancer: protocol AGO-GYN 5, AGO-study group. This evidence concerns the gene GNRH1 and endometrial cancer.